Mason Hawkins’s REGN Holdings & Trades

First Buy
Q1 2025
Duration Held
3 Quarters
Largest Add
Q1 2025
+114,880 shares
Current Position
144,607 shares
$81.31 M value

Mason Hawkins's REGN Position Overview

Mason Hawkins (via Southeastern Asset Management Inc/Tn/) currently holds 144.6K shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $81.31 M, representing 4.15% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 3 quarters.

Based on 13F filings, Mason Hawkins has maintained this position in REGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 45.7K shares. Largest reduction occurred in Q3 2025, reducing 16.0K shares.

Analysis based on 13F filings available since 2013 Q2

Mason Hawkins's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Mason Hawkins

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2025 +114,880 New Buy 114,880 $634.23
Q2 2025 +45,701 Add 39.78% 160,581 $525.00
Q3 2025 -15,974 Reduce 9.95% 144,607 $562.27

Mason Hawkins's Regeneron Pharmaceuticals Investment FAQs

Mason Hawkins first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q1 2025, acquiring 114,880 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mason Hawkins has held Regeneron Pharmaceuticals, Inc. (REGN) for 3 quarters since Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mason Hawkins's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2025, adding 114,880 shares worth $72.86 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Mason Hawkins's firm, Southeastern Asset Management Inc/Tn/, owns 144,607 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $81.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 4.15% of Mason Hawkins's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mason Hawkins's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 160,581 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.